Optimized organoid culture protocol for primary non-small cell lung cancer and predicting individual drug response
Year: 2026
Type: article
Abstract: Patient-derived organoids (PDOs) provide experimentally tractable models of non-small cell lung cancer (NSCLC), but their use is limited by variable establishment efficiency, overgrowth by normal airway epithelium, and incompletely standardized culture conditions. We developed an optimized, subtype-adapted NSCLC PDO culture system based on conditioned medium from irradiated Swiss 3T3-J2 fibroblasts (iJ2-CM), combined with the ROCK inhibitor Y-27632 and the TGF-β receptor inhibitor A83-01. Systematic cytokine screening identified insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF) as potent enhancers of the proliferation and viability of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) organoids, respectively. Matched histology and whole-exome sequencing demonstrated retention of lineage-associated features and tumor-associated genomic alterations. Importantly, this platform supports multiple downstream applications, including scalable drug screening and autologous immune cell co-culture assays, enabling the prediction of patient-specific responses to chemotherapy, targeted therapies, and immunotherapies. Collectively, this study establishes a physiologically relevant, subtype-tailored, and experimentally scalable NSCLC organoid platform with potential for mechanistic investigation, precision drug testing, and translational cancer research.
Source: Molecular Cancer
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,090
Awards: G4163530879, G9001399114
OpenAlex ID: W7236687713
